Phase II trial of lung chemoembolization
Description
Lung chemoembolization is a new treatment option for lung cancer or lung metastases that are not responding to systemic therapy and cannot be cured with surgery or radiation. Rather than injecting chemotherapy into a vein, the chemotherapy is delivered directly into the tumors, which potentially reduces side effects and improves efficacy. City of Hope is the only institution in the United States offering lung chemoembolization under a clinical research protocol.
Status
Accepting new patients
Primary Study Objective(s)
- Local progression free survival
- Safety
Core eligibility
Note: This is only a partial list of eligibility criteria.
Note: This is only a partial list of eligibility criteria.
Inclusion Criteria:
- Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy.
- Lung-dominant disease (majority of active tumor volume is in the chest).
Exclusion Criteria:
- ECOG performance status >2.
- Oxygen saturation < 92% on room air.
- FEV1 < 60%.
- No measurable treatable disease (for example, unable to measure tumor size on CT, or lung nodules are all < 1 cm).
- Pulmonary embolism within 3 months.
- Pneumonia within 1 month.
Learn more
